TICKERNERD
Menu
OMEROMERHealthcare · Biotechnology

OMER Stock Forecast: Omeros Corp. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$18
−2.69% on the day

The 3 Wall Street analysts covering Omeros Corp. hold a median 12-month price target of $28 — +49.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 31 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.3B
Ticker Nerd rank
91/ 100
Median analyst target
$28
Analysts covering
3
Revenue$28.5M
Operating income$74K
Net income$13.2M
Free cash flow$4.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.3%
1M
−3.2%
YTD
+7.3%
1Y
+145.2%
From 52W high
−12.4%
From 52W low
+193.6%
$6
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OMER stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Omeros Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
91/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
100
Momentum
95
Quality
78
Issuance
77
Growth
74
Value
68
Size
40
Accruals
33
Volatility
13

Revisions (100): Analysts have, on balance, been raising their forecasts.

Volatility (13): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OMER stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OMER, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26OMERHigh $33Median $28Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $22Median $28High $33

The green dot is the last close — the median target sits +49.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Oct 2026Cantor FitzgeraldReiteratesOverweight$22
22 Sept 2026Cantor FitzgeraldUpgradeOverweight$22
22 Sept 2026Cantor FitzgeraldUpgradeOverweight—
26 June 2026HC Wainwright & Co.MaintainsBuy—
26 June 2026HC Wainwright & Co.MaintainsBuy$40 → $33
10 June 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026HC Wainwright & Co.ReiteratesBuy—
21 Apr 2026D. Boral CapitalMaintainsBuy—
27 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026HC Wainwright & Co.MaintainsBuy—
24 Dec 2025D. Boral CapitalMaintainsBuy—
1 Dec 2025D. Boral CapitalMaintainsBuy—
14 Nov 2025D. Boral CapitalMaintainsBuy—
16 Oct 2025D. Boral CapitalMaintainsBuy—
15 Oct 2025D. Boral CapitalMaintainsBuy—
15 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Oct 2025NeedhamReiteratesHold—
15 Oct 2025WBB SecuritiesReiteratesStrong Buy—
3 Sept 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

OMER appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OMER vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Omeros Corp. returned +145.2% against +12.4% for the S&P 500, dividends included.

OMER vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26OMERS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OMER analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+81.6%
Analysts raising
1
Analysts cutting
0
Fundamentals

Omeros Corp. (OMER) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.1×

Cheaper than 45% of US stocks

Price / sales
34.7×

Cheaper than 6% of US stocks

Price / book
−25.9×

Cheaper than 99% of US stocks

EV / EBITDA
−20.9×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
188.4%

Higher than 95% of US stocks

Earnings growth (YoY)
—
Gross margin
97.2%

Higher than 99% of US stocks

Operating margin
0.3%

Higher than 46% of US stocks

Net margin
324.9%

Higher than 99% of US stocks

Returns & dividend
Return on equity
2.8%

Higher than 49% of US stocks

Return on assets
−18.7%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Omeros Corp. (OMER) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Omeros Corp. has a market value of $1.3B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $38.4M. The latest quarter grew 188.4% year on year.

  • Net income over the same four quarters: $124.8M, a 324.9% net margin.

  • Diluted earnings per share, trailing twelve months: $1.28.

  • Free cash flow in the twelve months to 30 June 2026: −$68.7M.

  • Omeros Corp. spent $9.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 72.1M.

  • Trailing P/E: 15.1×; forward P/E: 15.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Omeros Corp. employs 175 people — $220K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

OMER vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OMEROmeros Corp.$1.3B91
KARDKardigan, Inc.$1.3B0
DMRADamora Therapeutics, Inc.$1.3B41
TSHATaysha Gene Therapies, Inc.$1.3B41
NKTRNektar Therapeutics$1.3B46
LBRXLB Pharmaceuticals, Inc.$1.3B15
KRSAKorsana Biosciences, Inc.$1.4B37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Omeros Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OMER news & analysis

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Benzinga · 16 Oct 2026negative

Omeros said the EMA’s CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA after re-examining its original negative opinion from June. The headline also reports that the compassionate-use program is ending.

Why it matters — The opinion and reported end of the compassionate-use program are relevant to OMER watchers tracking the regulatory status and access to narsoplimab.

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Business Wire · 16 Oct 2026negative

Omeros announced that the EMA’s CHMP issued a negative opinion on its marketing authorization application for narsoplimab to treat TA-TMA, following re-examination of an earlier negative opinion.

Why it matters — The decision is relevant to OMER watchers because it reports an unfavorable outcome in the European review of the narsoplimab application.

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

Benzinga · 22 Sept 2026positive

Cantor Fitzgerald upgraded Omeros Corp, citing a better-than-expected launch of its transplant drug Yartemlea. The analyst suggested the drug could be bigger than previously anticipated.

Why it matters — The upgrade and favorable launch assessment point to stronger commercial prospects for Omeros's transplant drug Yartemlea, a key product for the company.

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Zacks Investment Research · 28 Aug 2026positive

Zacks Investment Research published an article asking whether Omeros (OMER) qualifies as a top stock pick for momentum investors. The piece frames the stock as potentially strong on momentum criteria.

Why it matters — A OMER watcher would care because it signals renewed analyst attention on the stock's momentum characteristics, which can influence investor perception.

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Investment Research · 25 Aug 2026positive

Omeros Corporation's 50-day simple moving average crossed above its 200-day simple moving average, a technical pattern known as a "golden cross," which the company reached at a key level of support. The article highlights this as an interesting development from a technical perspective.

Why it matters — OMER watchers would care because the golden cross is a widely followed technical signal that indicates a potential shift in the stock's momentum trend.

FAQ

Frequently asked questions about OMER stock

What is the OMER stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Omeros Corp. have a median 12-month price target of $28, with estimates ranging from $22 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OMER stock a buy right now?

Of the 3 analysts covering Omeros Corp., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omeros Corp. 91 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OMER?

As at 31 Oct 2026, Omeros Corp. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (100 of 100).

Will OMER stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +49.1% from the last close, and Ticker Nerd's factor model ranks Omeros Corp. 91 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OMER stock forecast for 2030?

No analyst covering Omeros Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $33 over the next 12 months.

How has OMER stock performed over the past year?

Omeros Corp. returned +145.2% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Omeros Corp. do?

Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics.

What is the latest news on OMER?

The most recent item we track (Benzinga, 16 Oct 2026): "Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends". Omeros said the EMA’s CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA after re-examining its original negative opinion from June. The headline also reports that the compassionate-use program is ending.

Company

About Omeros Corp.

Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies, and central nervous system disorders. Its portfolio includes commercial and development-stage programs designed to address unmet medical needs across hematology, nephrology, immunology, oncology, and addiction-related conditions. Omeros also works on targeted therapeutics that modulate the complement pathway, a key part of the immune system involved in several serious diseases. Headquartered in Seattle, Washington, Omeros Corp. plays a specialized role in the biotechnology market by advancing differentiated therapies from research through commercialization.

CEO Dr. Gregory A. Demopulos M.D. · 175 employees · United States · https://www.omeros.com